Authors
Potapov V.A.1, Musailov V.A.2, Avanesyan I.O.1, Tsyplyaev D.P.1
1 Russian University of Medicine, Moscow, Russia
2 Branch of the S.M. Kirov Military Medical Academy, Moscow
Abstract
The constant increase in the incidence of malignant neoplasms of the pancreas forces researchers to continue searching for the most effective methods of their diagnosis and treatment. The structure of ductal adenocarcinoma is found in 80-90% of all exocrine tumors of the pancreas. A key component of the diagnosis is the determination of further treatment tactics. A screening method for diagnosing pancreatic cancer is multispiral computed tomography. Radioimmunochemical tests of blood serum for 2 antigens – carbohydrate antigen (CA 19-9), cancer embryonic antigen are of practical importance among laboratory parameters.
Currently, systemic chemotherapy for pancreatic cancer is ineffective: the response to treatment is observed in less than 20% of patients, with a median life expectancy of about 6 months. However, studies by a number of authors have proven that adjuvant treatment, including chemotherapy and radiation therapy, increases long-term survival.
The current trend in pancreatic surgery is to move away from radicalism towards organ-preserving modifications of total duodenopancreatectomy, pancreatoduodenal resection. The problem of treating pancreatic cancer should be solved by combining the principles of selective choice of interventions, as well as determining clear indications for them. The search for new markers of pancreatic cancer screening, increasing the availability of radiation research methods, and the search for new chemotherapy drugs are promising. The search for reasonable options for reconstructive anastomoses remains relevant, allowing to preserve the physiological integrity of the body and, as a result, reduce mortality and the frequency of postoperative complications.
Keywords: pancreatic cancer, pancreatoduodenal resection, pancreatectomy, resectability.
References
1. Patyutko YuI. Hirurgiya raka organov biliopankreatoduodenal`noj zony`: Rukovodstvo dlya vrachej. Moscow: Medicina, 2007. (In Russ.)
2. Bazin IS, Garin AM. Sovremenny`e podxody` k terapii raka podzheludochnoj zhelezy`. Klinicheskie rekomendacii i algoritmy` dlya praktikuyushhix vrachej. Rus. med. zhurn. 2006; 6: 488-494. (In Russ.)
3. Solcia E, Capella C, Kloppel G. Tumors of the pancreas. AFIP Atlas of Tumor Pathology; 3rd ed. Washington DC: Armed Forces Institute of Pathology. 1997: 64.
4. Gubergricz NB, Xristich TN. Klinicheskaya pankreatologiya. Doneczk: Lebed`. 2000: 416 p. (In Russ.)
5. Kloppel G, Solcia E, Longnecker DS, et al. Histological typing of tumours of the exocrine pancreas. Organization WH. Ed. International Histological Classification of Tumours; 2nd ed. Berlin: Springer-Verlag, 1996.
6. Sarr MG, Behrns RE, van Heerden JA. Total pancreatectomy. An objective analysis of its use in pancreatic cancer. Hepatogastroenterology. 1993; 40(5): 418-421.
7. Kuby`shkin VA, Vishnevskij VA. Rak podzheludochnoj zhelezy`. M.: Medpraktika-M, 2003. (In Russ.)
8. Clemens M, Meyer J, Sulkowski U, et al. Perioperative staging and the Munster TNM classification in ampullary and pancreatic cancer. Langenbecks Arch. Chir. 1985; 365(3): 169-178.
9. Putov NV, Artem`eva NN, Koxanenko NYu. Rak podzheludochnoj zhelezy`. SPb.: Piter. 2005: 416 p. (In Russ.)
10. Kuby`shkin VA Rak podzheludochnoj zhelezy. Consilium Medicum. 2003; 5(8). Supple. (In Russ.)
11. Nagai H, Kuroda A, Morioka Y. Lymphatic and Local Spread of Tl and T2 Pancreatic cancer. A study of autopsy material. Ann. Surg. 1986; 204: 65-71.
12. Yoon KW, Heo JS, Choi DW, et al. Factors affecting longterm survival after surgical resection of pancreatic ductal adenocarcinoma. J. Kor. Surg. Soc. 2011; 81(6): 394-401.
13. Dronov AI, Kryuchina EA, Dobush RD. Kompleksnoe lechenie raka podzheludochnoj zhelezy. Ukrainskij zhurnal xirurgii. 2011; 4(13): 20-24. (In Russ.)
14. Catz Shir V, Schachter P, et al. Aggressive surgical approach in pancreatic cancer – is it justified? Harefuah. 2001; 140(2): 117-120.
15. Ramesh H. Management of Pancreatic Cancer: Current Status and Future Directions. Ind. J. Surg. 2010; 72(4): 285-289.
16. Ishikava O., Ohigashi H. i dr. Rasshirennaya pankreatektomiya pri rake golovki podzheludochnoj zhelezy: pokazaniya, operativnaya tekhnika, posleoperacionnoe vedenie // Ann. hir. gepatol. 1998. – T.3. – №1. – S.28-34. (In Russ.)
17. Pavlidis T, Pavlidis Е, Sakantamis А. Current opinion on lymphadenectomy in pancreatic cancer surgery. Hepatobil. Pancreat. Dis. Int. 2011; 10(1): 21-25.
18. Egorov V, Melekhina O, et al. Otdalennye rezul’taty i prognoz protokovoj adenokarcinomy golovki podzheludochnoj zhelezy posle standartnoj i rasshirennoj pankreatoduodenal’noj rezekcii. Ann. hir. gepatol. 2010; 1: 62. (In Russ.)
19. AndrénSandberg Åke. Prognostic Factors in Pancreatic Cancer. N. Am. J. Med. Sci. 2012; 4(1): 9–12.
20. Kabanov MYU, Solov’ev IA, Semencov KV, et al. Rak podzheludochnoj zhelezy – sovremennye vzglyady na problem. Ann. hir. gepatol. 2012; 4(4): 106-110. (In Russ.)
21. Popov AYu, Lishchishin VYa, Petrovsky AN, et al. Immediate outcomes of pancreatoduodenectomy after different digestive reconstruction procedures. Pirogov Russian Journal of Surgery. Khirurgiya. Zurnal im. N.I. Pirogova. 2021; 2: 14-19. (In Russ.) doi: 10.17116/hirurgia202102114.
22. Solodkiy VA, Kriger AG, Gorin DS, et al. Pancreaticoduodenectomy – results and prospects (two-center study). Pirogov Russian Journal of Surgery. 2023; 5: 13-21. (In Russ.) doi: 10.17116/hirurgia202305113.
23. Kokkinakis S, Kritsotakis EI, Maliotis N, et al. Complications of modern pancreaticoduodenectomy: A systematic review and meta-analysis. Hepatobiliary Pancreat Dis Int. 2022; 21(6): 527-537. doi: 10.1016/j.hbpd. 2022.04.006.
24. Shabunin AV, Bedin VV, Tavobilov MM, et al. Spleen-preserving total pancreatectomy for low-grade tumors. Khirurgiya. Zurnal im. N.I. Pirogova. 2023; 2: 5-12. (In Russ.)
25. Guo S, Zhou Q, Yang J, Tao J, Zhang J, Wang H. Duodenum-preserving pancreatic head resection compared to pancreaticoduodenectomy: A systematic review and network meta-analysis of surgical outcomes. Front Surg. 2023; 10: 1107613. doi: 10.3389/fsurg.2023.1107613.
26. Bedin VV, Tavobilov MM, Karpov AA, et al. The role of the left gastric vein in the preservation of the stomach during total duodenopancreatectomy in the modification of Botkin Hospital. Moscow Surgical Journal. 2023; 1: 18-26. (In Russ.) doi: 10.17238/ 2072-3180-2023-1-18-26.
27. Beger H, Matsumo S, Cameron JL. Diseases of the pancreas. Current surgical therapy. Springer – Berlin, Heidelberg, New York, 2008; 945.
28. Janot MS, Belyaev O, Kersting S, et al. Indications and Early Outcomes for Total Pancreatectomy at a High-Volume Pancreas Center. Clinical Study. HPB Surgery 2010; 10: 2-8. doi: 10.1155/2010/686702.
29. Murphy MM, Knaus WJ, Sing Chau Ng, et al. Total pancreatectomy: a national study. HPB 2009; 11: 476-482. doi: 10.1111/j.1477-2574.2009. 00076.x.
30. Muller MW, Friess H, Kleeff J, et al. Is there still a role for total pancreatectomy? Ann Surg 2007; 246(6): 966-974. doi: 10.1097/SLA.0b013e31815c2ca3.
31. Kent TS, Teviah E, Sanchez N. Conditional survival in pancreatic cancer: better than expected. HPB. 2011; 13: 876-880. doi: 10.1111/ j.1477-2574.2011.00379.x.
32. Granov DA, Pavlovskij AV, Tarazov PG. Maslyanaya arterial`naya ximioe`mbolizaciya: novy`j sposob terapii raka podzheludochnoj zhelezy. 2003; 49(5): 579-583. (In Russ.)
33. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant adiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. 1999; 230 (6): 776-782; discussion 782-784. doi: 10.1097/00000658-199912000-00006.
34. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004; 350 (12): 1200-1210. doi: 10.1056/NEJMoa032295.
35. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. J.A.M.A. 2008; 299(9): 1019-1026. doi: 10.1001/jama.299.9.1019.
36. Smeenk HG, Incrocci L, Kazemier G, et al. Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Dig. Surg. 2005; 22(5): 321-328. doi: 10.1159/000089250.
37. Granov DA, Pavlovskij AV, Tarazov PG. Novy`e vozmozhnosti regionarnoj ximioterapii raka podzheludochnoj zhelezy. Materialy` 10 Rossijskogo onkologicheskogo kongressa, Moscow, 2006: 29-31. (In Russ.)
38. Swartz M, Hsu C, Pawlik T, et al. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int. J. Radiat. Oncol. Biol. Phys. 2010; 76: 839-844. doi: 10.1016/j.ijrobp.2009.02.071.
39. Rasulov RI, Xamatov RK, Songolov GI, et al. Kompleksnoe lechenie bol`ny`x mestnorasprostranenny`m rakom golovki podzheludochnoj zhelezy`. Ann. xir. gepatol. 2013; 18(2): 75-89. (In Russ.)
40. Böttger TC, Störkel S, Wellek S, et al. Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study. Cancer. 1994; 73(1): 63-73.
41. Kriger AG. Actual issues of pancreatic tumor surgery. Pirogov Russian Journal of Surgery. 2021; 10: 5-12. (In Russ.) doi: 10.17116/hirurgia20211015.
42. Nikulin MP, Sel`chuk VYu, Chistyakov SS. Rak podzheludochnoj zhelezy`. Russkij Medicinskij Zhurnal. 2006; 242: 1726-1736. (In Russ.)
43. Polyakov AN, Patyutko YuI, Kudashkin NE, et al. Irreversible electroporation in locally advanced pancreatic cancer. Pirogov Russian Journal of Surgery. 2023; 10: 29-38. (In Russ.) doi: 10.17116/ hirurgia202310129.
44. Holland MM, Bhutiani N, Kruse EJ, et al. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. HPB: the official journal of the International HepatoPancreatoBiliary Association. 21(8): 1024-1031. doi: 10.1016/j.hpb.2018.12.004.
45. Martin RC, Scoggins CR, Egnatashvili V, et al. Arterial and venous resection for pancreatic adenocarcinoma: operative and longterm outcomes. Arch. Surg. 2009; 144(2): 154-159. doi: 10.1001/archsurg.2008.547.
46. Yeo CJ, Sohn TA, Cameron JL, et al. Periampullary adenocarcinoma Analysis of 5-yers survivors. Ann. Surg. 1998; 227(6): 821-831. doi: 10.1097/00000658-199806000-00005.
47. Bartoli FG, Arnone GB, Ravera G, et al. Pancreatic fistula and relative mortality in malignant disease after pancreaticoduodenectomy. Review and statistical metaanalysis regarding 15 years of literature. Anticancer Res. 1991; 11(5): 1831-1848.
48. Klempa I, Schwedes U, Usadel KH. Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin. Chirurg. 1979; 50(7): 427-431.
49. Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann. Surg. 2000; 232(3): 419-429. doi: 10.1097/ 00000658-200009000-00014.
50. Funovics JM, Zöch G, Wenzl E, et al. Progress in reconstruction after resection of the head of the pancreas. Surg. Gynecol. Obstet. 1987; 164(6): 545-548.
